Research programme - anti-CHI3L1 and PD-1 bispecific antibody therapeutics - Ocean Biomedical
Latest Information Update: 16 Aug 2023
At a glance
- Originator Ocean Biomedical
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Chitinase 3 like protein 1 inhibitors; Programmed cell death 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer